bpc 157 fda category 2 compounding panel votes to place popular peptide BPC-157 on list BPC-157 is shifting off FDA

BPC 157 is shifting off FDA Category 2 ahead of the July 23 PCAC vote, with RFK Jr. pushing expanded compounding access. The mechanism centers on its role in upregulating growth factors and Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law fda statement bpc 157 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies This just in: The FDA is proposing to move 14 commonly used peptides from Category 2 to Category 1 on the compounding review list If finalized, this shift could significantly change

SKU: 22647479017 · From equiscorp.hu